Conference Correspondent

The Mechanism of Action of CDK4/6 Inhibitors

Conference Correspondent 
Dr Matthew Goetz explains the rationale for using CDK4/6 inhibitors in patients with HR-positive metastatic breast cancer.

Related Items


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: